JPRN-UMIN000031763
Not yet recruiting
未知
Establishment of prevention method for head injury-related venous thromboembolism using anticoagulant. - The new protocol of prophylaxis for head injury-related venous thromboembolism by anticoagulation.
agasaki University Hospital Emergency Medical Center0 sites50 target enrollmentJune 1, 2018
Conditionshead injury
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- head injury
- Sponsor
- agasaki University Hospital Emergency Medical Center
- Enrollment
- 50
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The patients that hemostasis is not obtained. The patients with serious liver dysfunction or renal dysfunction. The patients with a history of Heparin\-induced thrombocytopenia (HIT). The patients of the drug irritable diathesis such as allergies. The patients who may be pregnant and breast feeding. The patients whom a primary investigator judged to be inadequate for the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Protecting against brain damage by improving treatment in neonates with hypoglycemia.E16.2Hypoglycaemia, unspecifiedDRKS00024086Heinrich-Heine Universität957
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-BEInstitut de Recherches Internationales Servier18,000
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMEUCTR2005-003700-10-GRInstitut de Recherches Internationales Servier18,000
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-ATInstitut de Recherches Internationales Servier18,000
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-ESaboratorios Servier S.L.18,000